Murray Valley encephalitis virus envelope protein (MVEV E protein)

The Murray Valley encephalitis virus (MVEV) envelope (E) protein is the primary structural component on the surface of the MVEV virion and plays a critical role in the viral life cycle (Source: UniProt: P14770). It is a class II viral fusion protein responsible for mediating host cell receptor binding and subsequent membrane fusion within the acidic environment of the endosome (Source: PubMed: 1654340). Structurally, the E protein is organized into three distinct domains (DI, DII, and DIII), with DIII typically serving as the primary site for receptor interaction and a major target for neutralizing antibodies (Source: PubMed: 10482579). In the context of disease, MVEV is a mosquito-borne flavivirus that causes Murray Valley encephalitis, a potentially fatal neurological condition characterized by inflammation of the brain (Source: Wikipedia). Because the E protein is the principal antigen for the host immune response, it is the central focus for vaccine development and the design of therapeutic monoclonal antibodies. Currently, there are no specific antiviral drugs approved for MVEV, but experimental strategies focus on blocking the E protein's ability to facilitate viral entry (Source: PubMed: 12134023). Therapeutic challenges include the risk of antibody-dependent enhancement (ADE) and significant serological cross-reactivity with other flaviviruses like West Nile and Japanese encephalitis viruses (Source: StatPearls: Flavivirus).

Other names

MVEV EEnvelope glycoprotein EE proteinMurray Valley encephalitis virus E protein

Neutralization of viral infectivity by blocking receptor binding or preventing pH-dependent membrane fusion within the endosome (Source: PubMed: 1654340).